NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Cancer Research

• Publication date

  2009-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-2632PMID 19276258PMCID PMC5806520
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

  2008cited by this paper
• Toll-like receptors and immune regulation: implications for cancer therapy

  2008cited by this paper
• Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

  2008cited by this paper
• Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector.

  2008cited by this paper
• Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant1

  2008cited by this paper
• Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF

  2008cited by this paper
• Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype

  2007cited by this paper
• Lack of Effective MUC1 Tumor Antigen-Specific Immunity in MUC1-Transgenic Mice Results from a Th/T Regulatory Cell Imbalance That Can Be Corrected by Adoptive Transfer of Wild-Type Th Cells1

  2007cited by this paper
• In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.

  2006cited by this paper
• CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

  2006cited by this paper
• NY-ESO-1: review of an immunogenic tumor antigen.

  2006cited by this paper
• Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination1

  2006cited by this paper
• CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients1

  2006cited by this paper
• CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.

  2005cited by this paper
• Regulatory T cells and mechanisms of immune system control

  2004cited by this paper
• Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma.

  2004cited by this paper
• Human CD4+CD25+ regulatory T cells.

  2004cited by this paper
• An integrated view of suppressor T cell subsets in immunoregulation.

  2004cited by this paper
• Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

  2004cited by this paper
• Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells.

  2004cited by this paper
• Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Supporting Online Material

  2003cited by this paper
• Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

  2003cited by this paper
• Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.

  2003cited by this paper
• T cell anergy.

  2003cited by this paper
• Increase of regulatory T cells in the peripheral blood of cancer patients.

  2003cited by this paper
• Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses

  2003cited by this paper
• Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1

  2002cited by this paper
• Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

  2001cited by this paper
• Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

  2000cited by this paper
• Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

  2000cited by this paper
• Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

  2000cited by this paper
• A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens

  1998cited by this paper
• Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.

  1996cited by this paper
• Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes.

  1996cited by this paper
• Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

  1995cited by this paper
• In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment.

  1993cited by this paper
• Genetic immunization is a simple method for eliciting an immune response

  1992cited by this paper

• A data-driven cartography of NSCLC vaccine research: Quantifying the paradigm shift toward immuno-oncology combination therapies

  2026cites this paper
• Personalizing DNA Cancer Vaccines

  2025cites this paper
• Advanced Technologies for Cancer Immunotherapy: Focus on Gastrointestinal Cancers.

  2025cites this paper
• Vaccine therapies for glioma: clinical frontiers and potential breakthrough

  2025cites this paper
• NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapy

  2024cites this paper
• Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens

  2024cites this paper
• Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials.

  2024cites this paper
• Antigen Delivery Systems: Past, Present, and Future

  2023cites this paper
• Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment

  2023cites this paper
• Plasmid DNA for Therapeutic Applications in Cancer

  2022cites this paper
• Nanoparticle-Based Delivery Systems for Vaccines

  2022cites this paper
• Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies

  2021cites this paper
• Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ

  2021cites this paper
• Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies

  2020cites this paper
• Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  2020cites this paper
• Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects

  2020cites this paper
• The Role of Proteases in Processing of Tumour Associated Antigen(NY-ES0-1)

  2019cites this paper
• Therapeutic cancer vaccine: building the future from lessons of the past

  2018cites this paper
• RESEARCH AND DEVELOPMENT OF GENETIC ENGINEERING IN MEDICINE AND AGRICULTURE IN THE UNITED STATES OF AMERICA

  2018cites this paper
• High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4+ and CD8+ T-Cell Epitopes

  2018cites this paper
• Current Strategies to Enhance Anti-Tumour Immunity

  2018influential citation
• DNA vaccines for prostate cancer.

  2017cites this paper
• Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer

  2017cites this paper
• Title Immunological milieu in the peritoneal cavity at laparotomy for gastriccancer

  2017cites this paper
• Gene Transfer to the Skin by Physical Methods of Delivery

  2017cites this paper
• Estudio de terapias antígeno-específicas para la prevención de la diabetes tipo 1 en el ratón nod

  2016cites this paper
• Preclinical and clinical development of DNA vaccines for prostate cancer.

  2016cites this paper
• Immunotherapy in prostate cancer: review of the current evidence

  2015cites this paper
• DNA vaccines, electroporation and their applications in cancer treatment

  2015cites this paper
• Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma

  2015cites this paper
• Clinical Implications of Epigenetic Alterations in Lung Cancer

  2014cites this paper
• Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review

  2014cites this paper
• Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2

  2014cites this paper
• Clinical Application of Plasmid-Based Cancer Vaccines

  2013cites this paper
• Enhancement of gene gun-induced vaccine-specific cytotoxic T-cell response by administration of chemotherapeutic drugs.

  2013cites this paper
• New targets for the immunotherapy of colon cancer—does reactive disease hold the answer?

  2013cites this paper
• Overcoming regulatory T‐cell suppression by a lyophilized preparation of Streptococcus pyogenes

  2013cites this paper
• Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature

  2013cites this paper
• Monitoring Regulatory Immune Responses in Tumor Immunotherapy Clinical Trials

  2013cites this paper
• DNA fusion vaccine designs to induce tumor‐lytic CD8+ T‐cell attack via the immunodominant cysteine‐containing epitope of NY‐ESO 1

  2013cites this paper
• Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications

  2013cites this paper
• Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination

  2013influential citation
• Strategies to Improve DNA Vaccine Potency: HPV-Associated Cervical Cancer as a Model System

  2012cites this paper
• NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer

  2012cites this paper
• Substantially Modified Ratios of Effector to Regulatory T Cells During Chemotherapy in Ovarian Cancer Patients Return to Pre-Treatment Levels at Completion: Implications for Immunotherapy

  2012cites this paper
• Trypanosoma cruzi Adjuvants Potentiate T Cell-Mediated Immunity Induced by a NY-ESO-1 Based Antitumor Vaccine

  2012cites this paper
• Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

  2012cites this paper
• Human Prostate Tumor Antigen–Specific CD8+ Regulatory T Cells Are Inhibited by CTLA-4 or IL-35 Blockade

  2012cites this paper
• Immunological milieu in the peritoneal cavity at laparotomy for gastric cancer.

  2012cites this paper
• Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer

  2012cites this paper
• Innate Immune Regulation and Cancer Immunotherapy

  2012cites this paper
• Immune Surveillance Tissue Antigen Profiling in Advanced Ovarian Cancer

  2012cites this paper
• A Stepwise Approach to the Development of Cancer Vaccines

  2012cites this paper
• Prostate cancer vaccines in clinical trials

  2012cites this paper
• Virus Adaptation and Treatment Oncolytic viruses : a step into cancer immunotherapy

  2011cites this paper
• Oncolytic viruses: a step into cancer immunotherapy

  2011cites this paper
• Therapeutic vaccination for cancer immunotherapy: Antigen selection and clinical responses

  2011cites this paper
• Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression

  2011cites this paper
• Gemcitabine depletes regulatory T‐cells in human and mice and enhances triggering of vaccine‐specific cytotoxic T‐cells

  2011cites this paper
• Multiple vaccinations: friend or foe.

  2011influential citation
• Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies

  2011cites this paper
• Therapeutic cancer vaccines: are we there yet?

  2011cites this paper
• ON IMMUNOTHERAPY AGAINST PROSTATE CANCER

  2010cites this paper
• Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1

  2010cites this paper
• Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection

  2010cites this paper
• Regulatory T cells in cancer.

  2010cites this paper
• Regulatory T cells exert checks and balances on self tolerance and autoimmunity

  2010cites this paper
• Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909

  2010cites this paper
• Aus der Universitätsklinik für Kinder- und Jugendmedizin Tübingen Abteilung Kinderheilkunde I mit Poliklinik (Schwerpunkt: Allgemeine Pädiatrie, Hämatologie und Onkologie)

  2010cites this paper
• B . Renaissance Through Steady Characterization

  2010influential citation
• Regulatory T cells exert checks and balances on self tolerance and

  2010cites this paper
• Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma

  2010cites this paper
• Mechanisms of T-cell inhibition: implications for cancer immunotherapy

  2010cites this paper
• Circumventing immune tolerance through epigenetic modification.

  2010cites this paper
• DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) Elicits Long-term T-cell Responses in Patients With Recurrent Prostate Cancer

  2010cites this paper
• Immunological markers of cancer vaccine efficacy and their clinical relevance.

  2009cites this paper
• CD8αα + T-cells and Immune Memory

  2009cites this paper
• Immunity and tolerance to the tumor-associated antigen MUC1

  2009cites this paper
• Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

  2009cites this paper
• Prospects for developing an effective particle-mediated DNA vaccine against influenza

  2009cites this paper
• Recent advances and hurdles in melanoma immunotherapy

  2009cites this paper
• Cancer/testis (CT) antigens: Potential targets for immunotherapy

  2009cites this paper
• International Journal of Molecular Sciences the Five Immune Forces Impacting Dna-based Cancer Immunotherapeutic Strategy

  year unknowncites this paper